S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
66,000% upside on tiny biotech? (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
66,000% upside on tiny biotech? (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
66,000% upside on tiny biotech? (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
66,000% upside on tiny biotech? (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Laser breakthrough could send stock soaring 2,467% (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
NASDAQ:LMAT

LeMaitre Vascular (LMAT) Stock Forecast, Price & News

$54.48
-0.60 (-1.09%)
(As of 09/29/2023 ET)
Compare
Today's Range
$54.30
$55.22
50-Day Range
$53.45
$64.70
52-Week Range
$41.78
$68.67
Volume
227,420 shs
Average Volume
104,198 shs
Market Capitalization
$1.21 billion
P/E Ratio
48.21
Dividend Yield
1.03%
Price Target
$69.50

LeMaitre Vascular MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
27.6% Upside
$69.50 Price Target
Short Interest
Bearish
3.13% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
1.08mentions of LeMaitre Vascular in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.83%
From $1.29 to $1.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.07 out of 5 stars

Medical Sector

27th out of 970 stocks

Surgical & Medical Instruments Industry

6th out of 99 stocks


LMAT stock logo

About LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LMAT Price History

LMAT Stock News Headlines

Med-Tech Stock Set To Rally!
With All The News That This Bio- Tech Stock Has had It Could Be Set To Rally!
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q2 2023 LeMaitre Vascular Inc Earnings Call
LeMaitre Q2 2023 Financial Results
LMAT - LeMaitre Vascular, Inc.
LeMaitre Vascular (NASDAQ: LMAT)
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
See More Headlines
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LMAT Company Calendar

Last Earnings
8/01/2023
Ex-Dividend for 8/31 Dividend
8/16/2023
Dividend Payable
8/31/2023
Today
10/01/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMAT
Employees
591
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$69.50
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+27.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$20.64 million
Pretax Margin
18.22%

Debt

Sales & Book Value

Annual Sales
$161.65 million
Cash Flow
$1.50 per share
Book Value
$12.19 per share

Miscellaneous

Free Float
19,502,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
0.97

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. George W. LeMaitreMr. George W. LeMaitre (Age 58)
    Chairman & CEO
    Comp: $840.11k
  • Mr. David B. RobertsMr. David B. Roberts (Age 59)
    Pres & Director
    Comp: $522.32k
  • Mr. Joseph P. Pellegrino Jr. (Age 58)
    CFO, Treasurer, Sec. & Director
    Comp: $463.58k
  • Mr. Trent G. KamkeMr. Trent G. Kamke (Age 52)
    Sr. VP of Operations
    Comp: $417.83k
  • Dr. George D. LeMaitreDr. George D. LeMaitre (Age 89)
    Founder and Chairman of Scientific Advisory Board
  • Mr. David C. Hissong
    Gen. Counsel
  • Ms. Kimberly L. Cieslak (Age 50)
    VP of Marketing
  • Mr. Daniel J. Mumford (Age 41)
    Director of HR
  • Mr. Ryan H. Connelly (Age 46)
    Sr. VP of Advanced Manufacturing Engineering
  • Mr. Andrew Hodgkinson (Age 47)
    Sr. VP of Clinical, Regulatory & Quality Affairs













LMAT Stock - Frequently Asked Questions

Should I buy or sell LeMaitre Vascular stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LMAT shares.
View LMAT analyst ratings
or view top-rated stocks.

What is LeMaitre Vascular's stock price forecast for 2023?

5 brokerages have issued 1-year price targets for LeMaitre Vascular's stock. Their LMAT share price forecasts range from $66.00 to $75.00. On average, they expect the company's share price to reach $69.50 in the next year. This suggests a possible upside of 27.6% from the stock's current price.
View analysts price targets for LMAT
or view top-rated stocks among Wall Street analysts.

How have LMAT shares performed in 2023?

LeMaitre Vascular's stock was trading at $46.02 on January 1st, 2023. Since then, LMAT shares have increased by 18.4% and is now trading at $54.48.
View the best growth stocks for 2023 here
.

When is LeMaitre Vascular's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our LMAT earnings forecast
.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced its earnings results on Tuesday, August, 1st. The medical instruments supplier reported $0.37 EPS for the quarter, beating the consensus estimate of $0.32 by $0.05. The medical instruments supplier had revenue of $50.12 million for the quarter, compared to analyst estimates of $48.29 million. LeMaitre Vascular had a trailing twelve-month return on equity of 9.33% and a net margin of 14.23%.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Tuesday, July 25th. Shareholders of record on Thursday, August 17th will be paid a dividend of $0.14 per share on Thursday, August 31st. This represents a $0.56 annualized dividend and a yield of 1.03%. The ex-dividend date of this dividend is Wednesday, August 16th.
Read our dividend analysis for LMAT
.

What ETFs hold LeMaitre Vascular's stock?

ETFs with the largest weight of LeMaitre Vascular (NASDAQ:LMAT) stock in their portfolio include Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Micro-Cap ETF (IWC).iShares U.S. Medical Devices ETF (IHI).

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.56 per share and currently has a dividend yield of 1.03%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 49.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 36.84% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its third quarter 2023 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $0.28-$0.33 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $46.50 million-$48.90 million, compared to the consensus revenue estimate of $45.91 million.

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

How do I buy shares of LeMaitre Vascular?

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $54.48.

How much money does LeMaitre Vascular make?

LeMaitre Vascular (NASDAQ:LMAT) has a market capitalization of $1.21 billion and generates $161.65 million in revenue each year. The medical instruments supplier earns $20.64 million in net income (profit) each year or $1.13 on an earnings per share basis.

How many employees does LeMaitre Vascular have?

The company employs 591 workers across the globe.

Does LeMaitre Vascular have any subsidiaries?
The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.
Read More
How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The official website for the company is www.lemaitre.com. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.

This page (NASDAQ:LMAT) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -